아시아 태평양 심혈관 대사 질환 시장 예측(2028년) – 유형별(심혈관 질환(CVD), 제2형 당뇨병, 고혈압 및 비만), 치료(ACE 억제제, 이뇨제, 글루코파지 등), 복용량( 정제, 주사제), 투여 경로(경구 및 정맥 주사), 최종 사용자(병원, 진료소, 홈케어 환경), 유통 경로(병원 약국, 소매 약국, 온라인 약국)

시장 소개

심장대사질환은 다음과 같은 일련의 이상과 증상이 특징입니다. 개인의 심혈관 질환 발병 위험. 고혈압, 비만, 인슐린 저항성, 이상지질혈증, 나쁜 콜레스테롤 수치(LDL), 포도당 내성 등이 증상 중 일부입니다. 심장대사증후군을 앓고 있는 사람은 제2형 당뇨병, 뇌졸중, 관상동맥질환(CAD), 심혈관질환(CVD) 등 생명을 위협하는 여러 가지 질병에 걸리기 쉽습니다.

또한, 심장대사 질환의 유병률 증가로 인해 예측 기간 동안 시장 성장이 강화될 것으로 예상됩니다. 그러나 저소득 및 중간 소득 국가(LMIC)의 심혈관 질환 진단 부족으로 인해 아시아 태평양 심혈관 대사 질환 시장의 성장이 제한되고 있습니다.

공급망 중단과 이에 대한 막대한 수요 코로나19 치료를 위한 효율적인 치료법으로 인해 아시아 태평양 지역의 의료 연구 산업이 중요한 상황에 놓였습니다. 이 전염병의 확산을 통제하기 위해 금지 조치가 취해졌습니다. 코로나19 팬데믹(세계적 대유행)은 아시아 태평양 지역 경제에 광범위하게 영향을 미쳤습니다. 인도(31,769,132), 일본(956,407), 중국(93,289), 한국(203,926) 등의 국가가 팬데믹으로 인해 부정적인 영향을 받았습니다. 마이너스 인플레이션, GDP 증가, 지역 실업률 급증 등 사회경제적 측면이 심각한 영향을 받았습니다. 최근 일본에서는 고혈압과 비만을 동시에 앓고 있는 환자가 증가하고 있다. 이들 환자는 코로나19 중증질환 고위험군에 속하므로 세심한 관찰과 집중적인 치료가 필요하다. 고혈압과 비교하여 비만의 정의는 연구/국가마다 일정하지 않으므로 고려가 필요합니다. 그러나 코로나19에 대한 CCB의 치료 메커니즘은 여전히 추가 조사와 무작위 대조 임상 시험을 기다리고 있다는 점에 유의해야 합니다.

시장 개요 및 역학

아시아 태평양 심장대사 질환 시장은 2021년 210억 9130만 달러에서 2028년 289억 5320만 달러에 이를 것으로 예상됩니다. 2021년부터 2028년까지 연평균 성장률(CAGR) 4.6%로 성장할 것으로 예상됩니다. 심혈관대사 질환(CMD)은 전 세계적으로 사망의 주요 원인 중 하나입니다. 이러한 질병은 주로 건강에 해로운 생활 방식, 신체 활동 부족, 흡연 및 건강에 해로운 식습관으로 인해 발생합니다. CMD에는 심혈관 질환(CVD), 당뇨병, 만성 신부전이 포함됩니다. 대부분의 심혈관 질환은 흡연, 건강에 해로운 식습관 선택, 비만, 신체 활동 부족 및 음주와 같은 행동 위험 요인을 해결함으로써 예방할 수 있습니다. 당뇨병은 기능적 치료법이 없는 생명을 위협하는 만성질환 중 하나이다. 이는 다양한 합병증을 일으키고 조기 사망의 전반적인 위험을 증가시킵니다. 심장 마비, 뇌졸중, 신부전, 다리 절단, 시력 상실 및 신경 손상은 당뇨병과 관련된 주요 합병증입니다. 흡연 증가, 운동부족, 음주, 건강에 해로운 식습관 등으로 인해 CMD를 하나 이상 갖고 있는 사람이 늘어나고 있습니다. 비만 유병률이 증가함에 따라 CMD로 고통받는 환자 기반도 늘어나고 있습니다. CMD 유병률이 급격히 증가함에 따라 적절한 심장 대사 질환 치료에 대한 필요성이 급증하여 아시아 태평양 심장 대사 질환 시장이 엄청나게 성장했습니다.

< u>주요 시장 부문

유형 면에서 심혈관 질환 부문은 2020년 아시아 태평양 심장대사 질환 시장에서 가장 큰 점유율을 차지했습니다. 치료 측면에서는 ACE 억제제 부문이 2020년 아시아태평양 심혈관대사질환 시장에서 가장 큰 점유율을 차지했고, 복용량 측면에서는 정제 부문이 2020년 아시아태평양 심혈관대사질환 시장에서 가장 큰 점유율을 차지했다. 투여 경로 측면에서 보면 경구 부문이 2020년 아시아 태평양 심혈관 대사 질환 시장에서 가장 큰 점유율을 차지했습니다. 최종 사용자 측면에서 보면 병원 부문이 2020년 아시아 태평양 심혈관 대사 질환 시장에서 가장 큰 점유율을 차지했습니다. 유통 채널에서는 병원 약국 부문 이 2020년에 가장 큰 시장 점유율을 차지했습니다.

주요 출처 및 상장 회사 u>

아시아 태평양 지역의 심장대사 질환 시장에 대한 이 보고서를 준비하기 위해 참조된 몇 가지 주요 1차 및 2차 소스는 회사 웹사이트, 연례 보고서, 재무 보고서입니다. , 국가 정부 문서, 통계 데이터베이스 등이 있습니다. 보고서에 나열된 주요 회사로는 Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc. 및 Kowa Company, Ltd.

보고서 구매 이유

아시아 태평양 심장대사 질환 시장 환경을 이해하고 강력한 수익을 보장할 수 있는 시장 부문을 식별
끊임없이 변화하는 시장 환경을 이해하고 이를 유지하기 위해 경쟁 우위
가장 유망한 판매 가능성이 있는 부문을 식별하여 아시아 태평양 심혈관 질환 시장에서 인수합병 및 파트너십 거래를 효율적으로 계획합니다.
다양한 부문의 시장 성과에 대한 통찰력 있고 포괄적인 분석을 통해 현명한 비즈니스 결정을 내리기 위해
아시아 태평양 지역의 시장 수익 예측을 얻기 위해 2021년부터 2028년까지 다양한 세그먼트를 기반으로 한 심장 대사 질환 시장

아시아 태평양 심장 대사 질환 시장 세분화

기준 유형

심혈관 질환(CVD)
제2형 당뇨병
고혈압
비만

치료에 따른

ACE 억제제
이뇨제
글루코파지
기타

복용량 기준

정제
주사

투여 경로별

경구
정맥 주사

최종 사용자에 의한

병원
클리닉
홈케어 설정 ;

유통 채널별

병원 약국 span>
소매 약국
온라인 약국

국가별

언급된 회사 Strong>

엘리 릴리 앤 컴퍼니.
바이엘 AG
노바티스 AG ;
Boehringer Ingelheim International Gmbh
Novo Nordisk A/S
AstraZeneca
Kowa Company, Ltd.
Cardax, Inc.

1.           Introduction 21
1.1         Scope of the Study. 21
1.2         The Insight Partners Research Report Guidance. 21
1.3         Market Segmentation. 23
1.3.7        Asia Pacific Cardiometabolic Diseases market – By Country. 25
2.           Asia Pacific Cardiometabolic Diseases Market – Key Takeaways 26
3.        Research Methodology 31
3.1         Coverage. 33
3.2         Secondary Research. 33
3.3         Primary Research. 34
4.           Asia Pacific Cardiometabolic Diseases Market – Market Landscape 35
4.1         Overview.. 35
4.2         PEST Analysis. 36
4.3         Expert Opinions. 37
5.           Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics 38
5.1         Market Drivers. 38
5.1.1        Increasing Prevalence of Cardiometabolic Diseases. 38
5.1.2        Innovation in Cardiometabolic Diseases Therapeutics. 38
5.2         Market Restraints. 39
5.2.1        Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs) 39
5.3         Market Opportunities. 40
5.3.1        Technological Advancements in CMD Diagnosis. 40
5.4         Future Trends. 40
5.4.1        Personalized Treatment for CMDs. 40
5.5         Impact Analysis. 41
6.           Asia Pacific Cardiometabolic Diseases Market – Regional Analysis 42
6.1         Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis. 42
7.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Type 44
7.1         Overview.. 44
7.2         Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44
7.3         Cardiovascular Disease (CVD) 45
7.3.1        Overview.. 45
7.3.2        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 46
7.4         Hypertension. 47
7.4.1        Overview.. 47
7.4.2        Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 47
7.5         Type 2 Diabetes. 48
7.5.1        Overview.. 48
7.5.2        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 48
7.6         Obesity. 50
7.6.1        Overview.. 50
7.6.2        Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 50
8.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment 52
8.1         Overview.. 52
8.2         Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52
8.3         ACE inhibitors. 53
8.3.1        Overview.. 53
8.3.2        ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn) 53
8.4         Diuretics. 55
8.4.1        Overview.. 55
8.4.2        Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 55
8.5         Glucophage. 56
8.5.1        Overview.. 56
8.5.2        Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 56
8.6         Others. 57
8.6.1        Overview.. 57
8.6.2        Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 57
9.           Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage 58
9.1         Overview.. 58
9.2         Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58
9.3         Tablet 59
9.3.1        Overview.. 59
9.3.2        Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 59
9.4         Injection. 60
9.4.1        Overview.. 60
9.4.2        Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 60
10.        Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration 61
10.1      Overview.. 61
10.2      Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61
10.3      Oral 62
10.3.1     Overview.. 62
10.3.2     Oral Market Revenue and Forecast to 2028 (US$ Mn) 62
10.4      Intravenous. 64
10.4.1     Overview.. 64
10.4.2     Intravenous Market Revenue and Forecast to 2028 (US$ Mn) 64
11.        Asia Pacific Cardiometabolic Diseases Market Analysis – By End User 66
11.1      Overview.. 66
11.2      Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66
11.3      Clinic. 67
11.3.1     Overview.. 67
11.3.2     Clinic Market Revenue and Forecast to 2028 (US$ Mn) 67
11.4      Hospital 68
11.4.1     Overview.. 68
11.4.2     Hospital Market Revenue and Forecast to 2028 (US$ Mn) 68
11.5      Homecare Settings. 70
11.5.1     Overview.. 70
11.5.2     Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn) 70
12.        Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel 72
12.1      Overview.. 72
12.2      Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72
12.3      Hospital Pharmacy. 73
12.3.1     Overview.. 73
12.3.2     Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 73
12.4      Retail Pharmacy. 74
12.4.1     Overview.. 74
12.4.2     Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 74
12.5      Online Pharmacy. 76
12.5.1     Overview.. 76
12.5.2     Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 76
13.        Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis 78
13.1      Asia Pacific: Cardiometabolic Diseases Market 78
13.1.1     Overview.. 78
13.1.2     Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 80
13.1.3     Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81
13.1.4     Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81
13.1.5     Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82
13.1.6     Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82
13.1.7     Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83
13.1.8     Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83
13.1.9     Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84
13.1.9.1       China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 85
13.1.9.1.1       China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86
13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86
13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87
13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87
13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88
13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88
13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89
13.1.15.1    Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90
13.1.15.1.1    Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90
13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91
13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92
13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92
13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93
13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93
13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94
13.1.21.1    India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million) 95
13.1.21.1.1    India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96
13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97
13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97
13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98
13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98
13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99
13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99
13.1.27.1    South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100
13.1.27.1.1    South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100
13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101
13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102
13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102
13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103
13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103
13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104
13.1.33.1    Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105
13.1.33.1.1    Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105
13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106
13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107
13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107
13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108
13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108
13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109
13.1.39.1    Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110
13.1.39.1.1    Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110
13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111
13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112
13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112
13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113
13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113
13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114
14.        Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 115
14.1      Asia Pacific: Impact Assessment of COVID-19 Pandemic. 115
15.        Asia Pacific Cardiometabolic Diseases Market – Industry Landscape 117
15.1      Overview.. 117
15.2      Growth Strategies in the Cardiometabolic Diseases Market (%) 118
15.3      Organic Developments. 119
15.3.1     Overview.. 119
15.4      Inorganic Developments. 122
15.4.1     Overview.. 122
16.        Company Profiles 124
16.1      Eli Lilly and Company. 124
16.1.1     Key Facts. 124
16.1.2     Business Description. 124
16.1.3     Products and Services. 125
16.1.4     Financial Overview.. 127
16.1.5     SWOT Analysis. 130
16.1.6     Key Developments. 131
16.2      Bayer AG.. 134
16.2.1     Key Facts. 134
16.2.2     Business Description. 134
16.2.3     Products and Services. 135
16.2.4     Financial Overview.. 135
16.2.5     SWOT Analysis. 138
16.2.6     Key Developments. 139
16.3      Novartis AG.. 141
16.3.1     Key Facts. 141
16.3.2     Business Description. 141
16.3.3     Products and Services. 142
16.3.4     Financial Overview.. 143
16.3.5     SWOT Analysis. 146
16.3.6     Key Developments. 147
16.4      Boehringer Ingelheim International GmbH.. 148
16.4.1     Key Facts. 148
16.4.2     Business Description. 148
16.4.3     Products and Services. 149
16.4.4     Financial Overview.. 150
16.4.5     SWOT Analysis. 154
16.4.6     Key Developments. 155
16.5      Novo Nordisk A/S. 157
16.5.1     Key Facts. 157
16.5.2     Business Description. 157
16.5.3     Products and Services. 158
16.5.4     Financial Overview.. 159
16.5.5     SWOT Analysis. 162
16.5.6     Key Developments. 163
16.6      AstraZeneca. 165
16.6.1     Key Facts. 165
16.6.2     Business Description. 165
16.6.3     Products and Services. 166
16.6.4     Financial Overview.. 167
16.6.5     SWOT Analysis. 170
16.6.6     Key Developments. 171
16.7      Cardax, Inc. 173
16.7.1     Key Facts. 173
16.7.2     Business Description. 173
16.7.3     Products and Services. 174
16.7.4     Financial Overview.. 174
16.7.5     SWOT Analysis. 177
16.7.6     Key Developments. 177
16.8      Kowa Company, Ltd. 178
16.8.1     Key Facts. 178
16.8.2     Business Description. 178
16.8.3     Products and Services. 179
16.8.4     Financial Overview.. 179
16.8.5     SWOT Analysis. 180
16.8.6     Key Developments. 181
17.        Appendix 182
17.1      About The Insight Partners. 182
17.2      Glossary of Terms. 183
LIST OF TABLES
Table 1.             Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81
Table 2.             Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81
Table 3.             Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82
Table 4.             Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82
Table 5.             Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83
Table 6.             Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83
Table 7.             China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86
Table 8.             China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87
Table 9.             China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87
Table 10.          China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88
Table 11.          China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88
Table 12.          China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89
Table 13.          Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91
Table 14.          Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92
Table 15.          Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92
Table 16.          Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93
Table 17.          Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93
Table 18.          Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94
Table 19.          India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97
Table 20.          India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97
Table 21.          India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98
Table 22.          India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98
Table 23.          India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99
Table 24.          India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99
Table 25.          South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101
Table 26.          South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102
Table 27.          South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102
Table 28.          South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103
Table 29.          South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103
Table 30.          South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104
Table 31.          Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106
Table 32.          Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107
Table 33.          Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107
Table 34.          Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108
Table 35.          Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108
Table 36.          Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109
Table 37.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111
Table 38.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112
Table 39.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112
Table 40.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113
Table 41.          Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113
Table 42.          Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114
Table 43.          Organic Developments in the Cardiometabolic Diseases Market 119
Table 44.          Inorganic Developments in the Cardiometabolic Diseases Market 123
Table 45.          Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market 183

LIST OF FIGURES
Figure 1.           Asia Pacific Cardiometabolic Diseases Market Segmentation. 23
Figure 2.           Asia Pacific Cardiometabolic Diseases Market Overview.. 26
Figure 3.           Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market 27
Figure 4.           Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million) 28
Figure 5.           Asia Pacific Cardiometabolic Diseases Market, Industry Landscape. 29
Figure 6.           Asia Pacific PEST Analysis. 36
Figure 7.           Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints. 41
Figure 8.           Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028. 43
Figure 9.           Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44
Figure 10.        Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 46
Figure 11.        Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 47
Figure 12.        Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 49
Figure 13.        Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 51
Figure 14.        Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52
Figure 15.        ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 54
Figure 16.        Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 55
Figure 17.        Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 56
Figure 18.        Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 57
Figure 19.        Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58
Figure 20.        Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 59
Figure 21.        Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 60
Figure 22.        Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61
Figure 23.        Oral Market Revenue and Forecasts to 2028 (US$ Mn) 63
Figure 24.        Intravenous Market Revenue and Forecasts to 2028 (US$ Mn) 65
Figure 25.        Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66
Figure 26.        Clinic Market Revenue and Forecasts to 2028 (US$ Mn) 67
Figure 27.        Hospital Market Revenue and Forecasts to 2028 (US$ Mn) 69
Figure 28.        Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn) 71
Figure 29.        Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72
Figure 30.        Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 73
Figure 31.        Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 75
Figure 32.        Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 77
Figure 33.        Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million) 79
Figure 34.        Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million) 80
Figure 35.        Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84
Figure 36.        China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86
Figure 37.        Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 91
Figure 38.        India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96
Figure 39.        South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 101
Figure 40.        Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 106
Figure 41.        Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 111
Figure 42.        Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 116
Figure 43.        Growth Strategies in the Cardiometabolic Diseases Market (%) 118

Eli Lilly and Company.
Bayer AG
Novartis AG
Boehringer Ingelheim International Gmbh
Novo Nordisk A/S
AstraZeneca
Kowa Company, Ltd.
Cardax, Inc.

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Report Code

Full Name

Country Name

Email Id

Phone Number

Job Title

Company

Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name Published Date

Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an.. May 2022

Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec.. May 2022

Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an.. May 2022

Report Name	Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an..	May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec..	May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000

$3000

GET FREE SAMPLE PDF
Inquire before Buying Inquire for Discount

Subscription Member Price: FREE
Get Subscription

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

Request for Free Sample

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.